source
- Roche to pay $700M upfront to Nurix for BTK degrader collaboration, deal up to $2.3BRoche announced a collaboration with Nurix Therapeutics to develop a BTK degrader for B cell malignancies. Roche will provide $700 million upfront, and the agreement could be worth up to $2.3 bill…
- Financing gaps keep $2 million gene therapies out of reach for many patientsWilliam Padula argues that the United States lacks the financial infrastructure to deliver ultra‑expensive gene therapies, even though they can cure diseases with a single dose. He notes that treat…